Study Links PAK5 to Poor Outcomes and Drug Resistance in HER2-Positive Breast Cancer

Source: Pharmacy Times articles

PAK5 is a protein that drives resistance to trastuzumab emtansine in patients with HER2+ breast cancer.
Read More